STOCK TITAN

Twist Bioscience CFO Adam Laponis sells 6,359 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp. Chief Financial Officer Adam Laponis reported a 7,828-RSU award and a sale of 6,359 common shares on November 16, 2026. The award vests 1/16th on each quarterly anniversary over 48 months, subject to continuous service through each vesting date. The 6,359-share sale at $103.6880 per share covered tax withholding connected to vesting of Performance Stock Units; the issuer’s equity incentive plans required the sale, which was not discretionary. No Rule 10b5-1 plan is reported.

Insider Laponis Adam
Role Chief Financial Officer
Sold 6,359 shs ($659K)
Share of Position Sold 5.1%
Type Security Shares Price Value
Sale Common Stock F1 6,359 $103.688 $659K
Grant/Award Common Stock F2 7,828 $0.00 $0.00
Holdings After Transaction: Common Stock — 126,329 shares (Direct)
Holdings Before and After: Common Stock, 124,860 to 126,329 shares (Direct)
Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
  1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units (""PSUs""). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a ""sell to cover"" transaction and do not represent discretionary trades by the Reporting Person.
  2. F2. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 16, 2026 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.
Shares sold 6,359 shares Sale on November 16, 2026, to cover tax withholding connected to vesting of Performance Stock Units
Sale price $103.6880 per share Sale on November 16, 2026
RSU award 7,828 RSUs Awarded November 16, 2026
RSU vesting period 48 months One-sixteenth vests on each quarterly anniversary, subject to continuous service
restricted stock unit (RSU) financial
"restricted stock unit award (RSU)"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
sell to cover financial
"funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
Performance Stock Units (PSUs) financial
"vesting of Performance Stock Units"
Performance stock units (PSUs) are a form of executive or employee pay that promise company shares only if pre-set performance goals are met over a defined period; think of them as a bonus paid in stock that arrives only when the company hits agreed targets. Investors watch PSUs because they affect the number of shares outstanding (dilution) and reveal how management’s pay is tied to financial or operational results, aligning incentives with shareholder outcomes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TWST shares did Adam Laponis sell, and at what price?

He sold 6,359 shares at $103.6880 per share on November 16, 2026. The sale covered tax withholding connected to vesting of Performance Stock Units and was required by the issuer’s equity incentive plans, rather than being discretionary. No Rule 10b5-1 plan is reported.

What RSU award did Adam Laponis receive from Twist Bioscience?

He received an award of 7,828 RSUs on November 16, 2026. One-sixteenth of the award vests on each quarterly anniversary over 48 months, subject to his continuous service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Laponis Adam

(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S6,359(1)D$103.688118,501D
Common Stock11/16/2026A7,828(2)A$0126,329D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units (""PSUs""). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a ""sell to cover"" transaction and do not represent discretionary trades by the Reporting Person.
2. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 16, 2026 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading